来自官方财务报表的收入、利润与现金流历史。
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients.
| 利润表 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| 总收入 | ₹137.5B | ₹113.2B | ₹105.6B | ₹94.6B |
| 毛利 | ₹102.3B | ₹84.3B | ₹77.7B | ₹66.4B |
| 营业利润（EBIT） | ₹34.4B | ₹29.3B | ₹25.7B | ₹21.4B |
| 净利 | ₹21.6B | ₹19.1B | ₹16.6B | ₹12.5B |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 TORNTPHARM 交互式查看器。 /companies/us/TORNTPHARM
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms